Am J Perinatol 2020; 37(12): 1280-1282
DOI: 10.1055/s-0040-1715643
Short Communication

A Case Report to Assess Passive Immunity in a COVID Positive Pregnant Patient

Lorraine E. Toner
1   Department of Obstetrics, Gynecology, and Reproductive Science, Icahn School of Medicine at Mount Sinai, New York, New York
2   Division of Maternal Fetal Medicine, Icahn School of Medicine at Mount Sinai, New York, New York
,
Shari E. Gelber
1   Department of Obstetrics, Gynecology, and Reproductive Science, Icahn School of Medicine at Mount Sinai, New York, New York
3   Maternal Fetal Medicine Associates, PLLC, Gynecology, and Reproductive Science, Icahn School of Medicine at Mount Sinai, New York, New York
,
Juan A. Pena
1   Department of Obstetrics, Gynecology, and Reproductive Science, Icahn School of Medicine at Mount Sinai, New York, New York
2   Division of Maternal Fetal Medicine, Icahn School of Medicine at Mount Sinai, New York, New York
,
Nathan S. Fox
1   Department of Obstetrics, Gynecology, and Reproductive Science, Icahn School of Medicine at Mount Sinai, New York, New York
3   Maternal Fetal Medicine Associates, PLLC, Gynecology, and Reproductive Science, Icahn School of Medicine at Mount Sinai, New York, New York
,
Andrei Rebarber
1   Department of Obstetrics, Gynecology, and Reproductive Science, Icahn School of Medicine at Mount Sinai, New York, New York
3   Maternal Fetal Medicine Associates, PLLC, Gynecology, and Reproductive Science, Icahn School of Medicine at Mount Sinai, New York, New York
› Author Affiliations

Abstract

Introduction Data regarding transplacental passage of maternal coronavirus disease 2019 (COVID-19) antibodies and potential immunity in the newborn is limited.

Case Report We present a 25-year-old multigravida with known red blood cell isoimmunization, who was found to be COVID-19 positive at 27 weeks of gestation while undergoing serial periumbilical blood sampling and intrauterine transfusions. Maternal COVID-19 antibody was detected 2 weeks after positive molecular testing. Antibodies were never detected on cord blood samples from two intrauterine fetal cord blood samples as well as neonatal cord blood at the time of delivery.

Conclusion This case demonstrates a lack of passive immunity of COVID-19 antibodies from a positive pregnant woman to her fetus, neither in utero nor at the time of birth. Further studies are needed to understand if passage of antibodies can occur and if that can confer passive immunity in the newborn.

Key Points

  • Passive immunity should not be assumed in COVID-19 infection in pregnancy.

  • Isoimmunization may impair passive immunity of certain antibodies.

  • Vaccination to or maternal infection of COVID-19 may not be protective for the fetus.



Publication History

Received: 01 July 2020

Accepted: 21 July 2020

Article published online:
13 August 2020

© 2020. Thieme. All rights reserved.

Thieme Medical Publishers
333 Seventh Avenue, New York, NY 10001, USA.